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Abstract
Background: In order to identify novel loci associated with Alzheimer’s disease (AD), we conducted a genome-
wide association study (GWAS) in the Spanish population.
Methods: We genotyped 1,128 individuals using the Affymetrix Nsp I 250K chip. A sample of 327 sporadic AD
patients and 801 controls with unknown cognitive status from the Spanish general population were included in
our initial study. To increase the power of the study, we combined our results with those of four other public
GWAS datasets by applying identical quality control filters and the same imputation methods, which were then
analyzed with a global meta-GWAS. A replication sample with 2,200 sporadic AD patients and 2,301 controls was
genotyped to confirm our GWAS findings.
Results: Meta-analysis of our data and independent replication datasets allowed us to confirm a novel genome-
wide significant association of AD with the membrane-spanning 4-domains subfamily A (MS4A) gene cluster
(rs1562990, P = 4.40E-11, odds ratio = 0.88, 95% confidence interval 0.85 to 0.91, n = 10,181 cases and 14,341
controls).
Conclusions: Our results underscore the importance of international efforts combining GWAS datasets to isolate
genetic loci for complex diseases.
Background
Alzheimer’s disease (AD) is the most common neurode-
generative pathology afflicting humans. The prevalence
of AD is rapidly growing due to a continuous increase
in life expectancy in developed countries [1]. AD is con-
sidered a complex neurodegenerative disorder that
causes a progressive neuronal loss in the brain, resulting
in a devastating cognitive phenotype, which ends with
the death of the patient.
Although its etiology is poorly understood, genetic
factors seem to play a pivotal role in AD. In fact, three
genes containing multiple full penetrance mutations,
APP (amyloid precursor protein), PSEN1 (presenilin 1)
and PSEN2 (presenilin 2), have been described for Men-
delian AD [2-4]. A non-necessary, non-sufficient com-
mon allele near the APOE (apolipoprotein E) transcript
is almost universally associated with non-Mendelian AD
[5]. In spite of research efforts in AD genetics, until very
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tently associated with the AD phenotype. However,
recent advances in genome wide association study
(GWAS) techniques have permitted the isolation of four
uncontroversial meta-GWAS-significant (P <5×E - 8 )
genetic markers associated with AD, which are located
near the CLU (clusterin), PICALM (phosphatidylinositol
binding clathrin assembly protein), CR1 (complement
component (3b/4b) receptor 1) and BIN1 (bridging inte-
grator 1) genes [6-8]. No other result derived from
genetic studies has been consistently validated for AD
other than these loci.
Materials and methods
Samples and datasets
In order to identify new AD-associated SNPs, we
designed a new case-control GWAS in the Spanish
population. We genotyped 1,128 individuals using the
Affymetrix Nsp I 250 K chip as previously described [9].
A sample of 327 sporadic AD patients diagnosed as pos-
sible or probable AD in accordance with the criteria of
the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’sD i s e a s e
and Related Disorders Association (NINCDS-ADRDA)
[10] by neurologists at the Virgen de Arrixaca University
Hospital in Murcia (Spain) and 801 controls with
unknown cognitive status from the Spanish general
population were included in our initial study. Mean
(standard deviation (SD)) age at recruitment was 79.1
(6.8) years in cases and 52.0 (8.9) in controls. The corre-
sponding number (percentage) of female samples was
228 (71.5%), and 348 (45.4%), respectively. Mean (SD)
age at AD diagnosis in cases was 76.2 (6.9) years.
Informed consent was obtained from each blood donor.
Institutional review board approval for this research was
obtained from the regional Ministry of Health (Comuni-
dad Autónoma de Murcia) and conforms to the World
Medical Association’s Declaration of Helsinki.
To increase the power of our study to detect small
genetic effects, we combined our results with those of
four other public GWASs, including the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) longitudinal
study, the GenADA study, the National Institute of
Aging (NIA) Genetic Consortium for Late Onset Alzhei-
mer’s Disease study, and the Translational Genomics
Research Institute (TGEN) GWAS [11-14]. The ADNI
longitudinal study, which is aimed at identifying biomar-
kers of AD using the Illumina 610 Quad platform and
extensive neuroimaging techniques. A total of 187 early
AD cases and 229 elderly controls were initially identi-
fied to be included in this study [15]. ADNI data used
in the preparation of this article were obtained from the
ADNI database [16]. The ADNI was launched in 2003
by the NIA, the National Institute of Biomedical
Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical
companies and non-profit organizations as a $60 mil-
lion, 5-year public-private partnership. The primary goal
of ADNI has been to test whether serial magnetic reso-
nance imaging (MRI), positron emission tomography
(PET), and other biological markers are related to the
progression of mild cognitive impairment and early AD.
Determination of sensitive and specific markers of very
early AD progression is intended to aid researchers and
clinicians to develop new treatments and monitor their
effectiveness, as well as reduce the time and cost of clin-
ical trials. The Principal Investigator of this initiative is
Michael W Weiner, MD (VA Medical Center and Uni-
versity of California - San Francisco). ADNI is the result
of efforts of many co-investigators from a broad range
of academic institutions and private corporations, and
subjects have been recruited from over 50 sites across
the US and Canada. The initial goal of ADNI was to
recruit 800 adults aged 55 to 90 years to participate in
the research - approximately 200 cognitively normal
older individuals to be followed for 3 years, 400 people
with mild cognitive impairment to be followed for 3
years and 200 people with early AD to be followed for 2
years. For up-to-date information, visit ADNI’s webpage
[16]. The GenADA study includes 801 cases meeting
the NINCDS-ADRDA and DSM-IV criteria for probable
AD and 776 control subjects without family history of
dementia that were genotyped using the Affymetrix 500
K GeneChip Array set [12,17]. The NIA Genetic Con-
sortium for Late Onset Alzheimer’s Disease study ori-
ginally included 1,985 cases and 2,059 controls
genotyped with the Illumina Human 610 Quad platform
[13]. However, using family trees provided, we excluded
all related controls and kept only one case per family. A
total of 1,077 cases and 876 unrelated controls were eli-
gible for our study. The TGEN GWAS study included
643 late onset AD cases and 404 controls from a neuro-
pathological cohort and 197 late onset AD cases and
114 controls from a clinical cohort all genotyped with
the Affimetrix 500 K GeneChip Array set [11].
Aggregated data from Harold et al.[ 7 ]a n dH uet al.
[18] were also used as ‘in silico’ replication studies.
Available data from Harold et al. include allelic odds
ratio (OR) estimates and P-values for the 731 top signals
from their study of 3,941 cases and 7,848 controls. A
comprehensive list of allelic OR estimates and P-values
for 451,001 SNPs was obtained from the supplementary
material of Hu et al. These data correspond to the
GWAS described in their manuscript that includes
1,034 cases and 1,186 controls.
Finally a replication sample with 2,200 sporadic AD
patients diagnosed as possible or probable AD in accor-
dance with NINCDS-ADRDA criteria by neurologists at
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Cantoblanco (Madrid), along with 2,301 general popula-
tion controls was used. Mean (SD) age at recruitment in
this sample was 82.0 (7.7) years in cases and 54.7 (12.4)
in controls. The corresponding number (percentage) of
female samples was 1,559 (71.0%), and 1,540 (67.1%),
respectively. Mean (SD) age at AD diagnosis was 77.9
(7.6) years.
GWAS quality control analyses
We performed extensive quality control on the five
datasets with individual genotypes included in the analy-
sis (Murcia, ADNI, GenADA, NIA, TGEN) using Affy-
metrix Genotyping Console software and Plink [19]. For
our genotyped samples, only individuals with a sample
call rate above 93% were later re-called with the Baye-
sian Robust Linear Model with Malalanobis (BRLMM)
distance algorithm, ran with default parameters, which
improves call rates in most samples. Self-reported sex
was compared to sex assigned by chromosome X geno-
types, and discrepancies were resolved or samples
removed. For all datasets, the program Graphical Repre-
sentation of Relationships (GRR) [20] was used to check
sample relatedness and to correct potential sample mix-
ups, duplications, or contaminations. SNPs were selected
to have a call rate above 95% (in each case, control, and
combined group, within each dataset), and a minor
allele frequency above 1% (again in each case, control,
and combined group, within each dataset). SNPs that
deviated grossly from Hardy-Weinberg equilibrium (P-
value < 10-4) in control samples were also removed. We
also removed SNPs with a significantly different rate of
missingness (P-value < 5 × 10-4) between case and con-
trol samples within each dataset.
To ensure all SNPs across all datasets were typed
according to the same DNA strand, each dataset was
normalized using HapMap phase 2 data as the reference
set. We merged each study with the HapMap CEU sam-
ples and compared genotype calls. SNP calls were
flipped (if typed on the opposite strand) or removed (if
the strand could not be undoubtedly assigned) as neces-
sary. We also removed SNPs that were significantly
associated with ‘study status’. That is, we labeled control
individuals from each study as cases and HapMap CEU
individuals as controls, and removed SNPs with P-values
< 10-6 in a test for association.
Principal components analysis
Principal components analysis was carried out with
EIGENSOFT [21,22] to evaluate population admixture
within each population, and to identify individuals as
outliers. We ran the SMARTPCA program with default
parameters, excluding chromosome X markers. To mini-
mize the effect of linkage disequilibrium in the analysis,
we also excluded markers in high linkage disequilibrium
(with the indep-pairwise option in Plink) and long-range
linkage disequilibrium regions reported previously or
detected in our population. Individuals identified as out-
liers (six SDs or more along one of the top ten principal
components) were removed from all subsequent ana-
lyses. Principal component analysis was run within each
dataset, and also together with other HapMap European
and worldwide populations to detect individuals of dif-
ferent ethnicities.
Imputation
Since different platforms were used in the five GWASs
analyzed, we imputed genotypes using HapMap phase 2
CEU founders (n = 60) as a reference panel using two
different methodologies: Plink [19] and Mach [23]. Gen-
ome-wide imputation was carried out with plink, and
genotype calls with high quality scores were used in
subsequent association analyses. Best association results
were also imputed with Mach 1.0 to confirm the consis-
tency of imputed genotypes.
After all these quality control and preparatory steps,
the Murcia study kept 1,034,239 SNPs for 319 cases and
769 controls; the ADNI dataset kept 1,794,894 SNPs for
164 cases and 194 controls; the GenADA dataset kept
1,436,577 SNPs for 782 cases and 773 controls; the NIA
dataset kept 1,738,663 SNPs for 987 cases and 802 con-
trols.; and the TGEN dataset contained 1,237,568 SNPs
in 757 cases and 468 controls. A total of 696,707 SNPs
were common to all GWASs whereas 1,098,485 and
1,951,797 SNPs were common to at least four and two
studies, respectively.
Replication genotyping
The MS4A (membrane-spanning 4-domains, subfamily
A) cluster polymorphism rs1562990 was genotyped in
2,200 cases and 2,301 controls from the Spanish popula-
tion using real-time PCR coupled to fluorescence reso-
nance energy transfer (FRET). Primers and probes
employed for these genotyping protocols are summar-
ized in Additional file 1. The protocols were performed
in the LightCycler
® 480 System instrument (Roche
Diagnostics, Indianapolis, IN, USA). Briefly, PCR reac-
tions were performed in a final volume of 20 μlu s i n g
20 ng of genomic DNA, 0.5 μM of each amplification
primer, 0.20 μM each detection probe, and 4 μLo f
LC480 Genotyping Master (5X, Roche Diagnostics). We
used an initial denaturation step of 95°C for 5 minutes,
followed by 45 cycles of 95°C for 30 s, 55°C for 30 s,
and 72°C for 30 s. Melting curves were 95°C for 2 min-
utes (ramping rate 4.4°C/s), 62°C for 30 s (ramping rate
of 1°C/s), 40°C for 30 s (ramping rate of 1°C/s), and 68°
C for 0 s (ramping rate of 0.15°C/s). In the last step of
each melting curve, a continuous fluorimetric register
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per degree celsius. Melting peaks and genotype calls
were obtained by using the LightCycler
® 480 software
(Roche). In order to confirm genotypes, selected PCR
amplicons were bi-directionally sequenced using stan-
dard capillary electrophoresis techniques.
Association analysis
Unadjusted single-locus allelic (1 degree of freedom)
association analysis within each independent sample,
and of the combined sample, was carried out using
Plink. We combined data from these five GWAS data-
sets using the meta-analysis tool in Plink selecting only
those markers common to at least four of these studies
(1,098,485 SNPs). The most promising and consistent
results from these single-locus analyses were compared
to the aggregated estimates available from Harold et al.
[7]and Hu et al. [18]. Finally, a replication sample of
2,200 cases and 2,301 controls from the Spanish popula-
tion was used to validate rs1562990. Although the main
results of the study are unadjusted estimates and P-
values from the allelic test, multivariate logistic regres-
sion models were also used to adjust estimates for the
combined Spanish samples (Murcia GWAS and the
replica) by age, sex, and APOE E+ status using the
Logistic option in Plink. A final meta-analysis and Forest
plot for the marker rs1562990, including the five origi-
nal GWASs plus the two ‘in silico’ replicas and the final
replica, was done with the Stata 10.0 (College Station,
TX, USA) metan command.
Results and discussion
The meta-analysis of the five GWASs (Murcia, ADNI,
GenADA, NIA, and TGEN) included a total of 3,009
cases and 3,006 controls. A total of 696,707 SNPs were
common to all GWAS whereas 1,098,485 SNPs were
common to at least four. Figure 1 shows a Manhattan
plot with the results of this GWAS meta-analysis. We
identified several signals,m o s to ft h e mf o u n di np r e -
viously reported AD loci (Additional file 2). The only
GWAS-significant result (P = 4.71 × 10-15) corre-
sponded to rs10402271 in chromosome 19, a marker
located 78 kb upstream of the APOE locus. Other sug-
gestive signals were located in chromosome 2
(rs7561528, located 25 kb downstream of the BIN1
locus), chromosome 22 (rs7561528 and rs13447284),
and multiple regions within chromosome 11. In fact,
among the top 100 markers, 45 were located on chro-
mosome 11 (Additional file 3). Chromosome 11 con-
tains several independent suggestive association signals,
including the HBG2 (hemoglobin, gamma G) locus
(peak association at rs10838245, P = 1.04E-5), MSE4A
gene family cluster (peak association at rs7626344, P =
5.48E-6), GAB2 (GRB2-associated binding protein 2;
rs450128, P = 2.79E-6), downstream PICALM
(rs4944558, P = 1.50E-4), and putative downstream gene
BC038205 (rs7935502, P = 7.47E-5).
We then conducted an ‘in silico’ replication of our
results using aggregated data from Harold et al.[ 7 ]
(which includes the top 731 signals from their study,
many of them also located in chromosome 11) and Hu
et al. [18] (a comprehensive rank of 451,001 SNPs geno-
typed in their GWAS). Although limited by the number
of SNPs available from these studies, the new meta-ana-
lysis yielded quite interesting results, with a total of 17
markers above the GWAS significance level (Additional
file 4). Several signals belonged to known AD loci:
APOE with eight SNPs, PICALM (three SNPS, the most
significant being rs536841, P = 2.96E-9), CLU (rs569214,
P =4 . 1 1 E - 8 ) ,a n dBIN1 (rs744373, P = 2.13E-9). Most
important, we found four SNPs that belong to a region
in chromosome 11q12 not previously reported as
GWAS significant for AD. The new peak for AD is
located within the MS4A cluster and the most signifi-
cant SNP was rs1562990 (OR 0.87; P = 3.01E-10).
Since we have previously published replication studies
of APOE, CLU, PICALM and BIN1 signals in the Span-
ish population [8,24], we decided to replicate only
rs1562990 in 2,200 cases and 2,301 controls from the
this population. Importantly, the result of this new inde-
pendent replica was fully consistent, yielding a signifi-
cant OR of 0.90 (95% confidence interval (CI) 0.83 to
0.98; P = .01). Detailed results for the original Spanish
GWAS dataset, Spanish replica sample, and the com-
bined Spanish dataset are described in Additional file 5.
We fitted a multivariate logistic regression model for
the combined Spanish sample in which we adjusted for
age, sex and APOE. The adjusted OR estimate was vir-
tually unchanged (OR 0.87; 95% CI 0.74 to 1.04; P =
0.12), suggesting that the observed effect is not influ-
enced by age, sex or APOE in our series.
Finally, combining this new replication in a final meta-
analysis together with the five original GWASs and the
two ‘in silico’ replications yields an OR of 0.88 (95% CI
0.85 to 0.91; P = 4.4E-11), which exceeds the accepted
threshold for testing multiple comparisons (that is, P <
5E-8). A total of 10,181 cases and 14,341 controls are
included in this combined analysis. The magnitude of
effect is consistent across studies, with all ten estimates
between 0.74 and 0.91 (Figure 2).
Our results point to the existence of a new AD locus
located within the MS4A cluster at 11q12. Coinciden-
tally, during the drafting of this manuscript two inde-
pendent articles emerged reaching similar conclusions
regarding MS4A cluster involvement in AD [25,26]. Cer-
tainly, the SNP markers described in the three studies
are different, but they are only 83,871 bp apart. How-
ever, our signal is closer to rs4938933 (reported by Naj
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rs1562990. In any case, peak markers observed in these
studies are located in the same haplotypic block and
have identical effect size and direction, which strongly
suggest that they are tracking the same functional
variant.
It is important to mention that sample overlapping
exists between these studies. Nonetheless, at least three
full datasets contained in our study (comprising 7,809
individuals, 31%) do not overlap with previous published
works. Importantly, meta-analysis using only these non-
overlapping samples also rendered a significant associa-
tion with the MS4A region (OR = 0.897; 95% CI 0.838
to 0.961; P = 0.0018). Therefore, our study could be
considered an independent replication of the involve-
ment of the MSA4A gene cluster in AD. The concur-
rence of three independent studies reaching the same
conclusion by employing different SNP platforms, impu-
tation methods and datasets underscores the strength
and consistency of this new AD locus, at least in Eur-
opean populations. Further studies will be necessary to
corroborate its involvement in AD etiology in other eth-
nic groups.
The MS4A family includes at least 16 paralogues. Each
gene has been probably generated by an ancestral cas-
cade of intrachromosomal duplications during vertebrate
evolution. Unfortunately, this gene family is poorly char-
acterized, although a role in immunity has already been
shown for several members this cluster, including
MS4A1 (CD20), MS4A2 and MS4A4B [28]. However,
the function in humans of many other members remains
obscure and a more general involvement of MS4A
family members as ion channel adaptor proteins in non-
immune tissues is suspected [28].
The rs1562990 marker maps between MS4A4E and
MS4A4A members of the cluster. However, we detected
a critical linkage disequilibrium haplotype block span-
ning 163 kb that comprises three members of the family
(MS4A2, MS4A6A,a n dMS4A4) and the top four meta-
GWAS-significant markers (Additional file 4). With the
available data it is difficult to determine the precise
location of the functional variant associated with AD, or
Figure 1 Manhattan plot of meta-analysis of five GWASs (Murcia, ADNI, GenADA, NIA, and TGEN), including a total of 3,009 cases and
3,006 controls. A total of 696,707 SNPs were common to all GWASs whereas 1,098,485 SNPs were common to at least four studies.
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etiology. Furthermore, it may be the case that a func-
tional non-coding variant within the cluster might alter,
by cis-regulation, the function of other members of the
cluster simultaneously. Re-sequencing and functional
studies of candidate mutations could help resolve this
question.
The most centromeric gene within the critical block,
MS4A2, encodes a protein that binds to the Fc region of
immunoglobulin epsilon. MS4A2 seems responsible for
i n i t i a t i n gt h ea l l e r g i cr e s p o n s eb yb i n d i n go fa l l e r g e nt o
receptor-bound IgE, which leads to cell activation and
the release of mediators (such as histamine). This signal
cascade is responsible for the manifestations of allergy
[29]. Indeed, polymorphisms within the MS4A2 gene
have been associated with susceptibility to aspirin-intol-
erant asthma [30], and some epidemiological studies
suggest a link between asthma and AD [31]. Conse-
quently, a hypothetical link between MS4A2 and AD
would add new evidence in favor of the AD neuroin-
flammatory hypothesis, suggesting a role for the
immune system in the pathogenesis of AD. The other
genes within the candidate block are poorly character-
ized and it is not easy to delineate a plausible hypothesis
for them yet.
Data access
GWAS data from Spanish patients is available for quali-
fied researchers after institutional review board approval
by the Comunidad Autónoma de la Región de Murcia
(Spain). Send requests to Dr Carmen Antúnez Almagro
mcarmen.antunez@carm.es.
Conclusions
We report a new genetic locus associated with AD. Our
work underscores the importance of the combination of
new GWAS data with existing datasets in order to iden-
tify novel signals that can only emerge through meta-
analysis. We are confident that the increasing sample
size of GWASs, the growing number of publicly avail-
able GWAS datasets, the higher marker density and the
development of novel strategies for GWAS data analysis
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Figure 2 Meta-analysis and Forest plot of rs1562990, reporting odds ratio (OR) with 95% confidence interval (CI), study-specific
weight, sample size and minor allele frequency (MAF) in cases and controls, for each study. The figure shows the remarkable consistency
of the OR across studies.
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the future and might contribute to decreasing the miss-
ing piece of heritability in neurodegenerative disorders.
Additional material
Additional file 1: Table S1 - primers and probes employed for Real-
time detection of MS4A cluster rs1562990 marker. Molecular
Information for rs1562990 genotyping.
Additional file 2: Table S2 - top 100 results in the meta-analysis
including five initial GWAS. Best results obtained in our study. CHR,
chromosome; A1, allele 1; A2, allele 2; N, number of studies in the meta-
analysis contributing to the overall estimate of the marker; P, P-value
from fixed effects model; P(R), P-value from random effects model; OR,
pooled odds ratio estimate from fixed effects model; OR(R), pooled odds
ratio estimate from random effects model; Q, P-value for Cochrane’sQ
statistic; I, I
2 heterogeneity index.
Additional file 3: Table S3 - GWAS plus aggregated data from
Harold et al. and Hu et al. GWAS-significant markers obtained after in
silico replications. CHR, chromosome; A1, allele 1; A2, allele 2; N, number
of studies in the meta-analysis contributing to the overall estimate of the
marker; P, P-value from fixed effects model; P(Random), P-value from
random effects model; OR, pooled odds ratio estimate from fixed effects
model; OR(Random), pooled odds ratio estimate from random effects
model; Q, P-value for Cochrane’s Q statistic; I, I
2 heterogeneity index.
Additional file 4: Table S4 - MS4A rs1562990 minor allele frequency
(MAF), Genotype distribution, effect estimates, and significance in
the Spanish series. Table describing the results of MS4A cluster region
in the Spanish population.
Additional file 5: Figure S1 - Manhattan plot with results from the
meta-analysis of the five initial GWASs for markers in chromosome
11. MetaGWAS results obtained for chromosome 11.
Additional file 6: File S1 - Alzheimer’s Disease Neuroimaging
initiative (ADNI) active investigators. Full list of ADNI co-investigators
(alphabetical order).
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